Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 2658 to 2707 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2658\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 13, MEMBER 4 (NA+/SULFATE COTRANSPORTER SUT-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0480531\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.228892\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209937875\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC13A4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2659\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 13, MEMBER 1 (RENAL SODIUM/SULFATE COTRANSPORTER) (NA(+)/SULFATE COTRANSPORTER) (HNASI-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0481673\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.229436\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209937848\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC13A1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2660\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SOLUTE CARRIER FAMILY 13, MEMBER 2 (RENAL SODIUM/DICARBOXYLATE COTRANSPORTER) (NA(+)/DICARBOXYLATE COTRANSPORTER 1) (NADC-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0401827\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.191403\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209937671\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC13A2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2661\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PHOSPHATIDATE CYTIDYLYLTRANSFERASE 1 (EC 2.7.7.41) (CDP-DIGLYCERIDE SYNTHETASE 1) (CDP-DIGLYCERIDE PYROPHOSPHORYLASE 1) (CDP- DIACYLGLYCEROL SYNTHASE 1) (CDS 1) (CTP:PHOSPHATIDATE CYTIDYLYLTRANSFERASE 1) (CDP-DAG SYNTHASE 1) (CDP-DG SYNTHETASE 1). [Source\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.558539\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.66089\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209906836\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDS1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2662\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ELECTRON TRANSFER FLAVOPROTEIN-UBIQUINONE OXIDOREDUCTASE, MITOCHONDRIAL PRECURSOR (EC 1.5.5.1) (ETF-QO) (ETF-UBIQUINONE OXIDOREDUCTASE) (ETF DEHYDROGENASE) (ELECTRON-TRANSFERRING- FLAVOPROTEIN DEHYDROGENASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.114957\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.548489\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209588524\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ETFDH\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2663\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POLYMYOSITIS/SCLERODERMA AUTOANTIGEN 2 (AUTOANTIGEN PM/SCL 2) (POLYMYOSITIS/SCLERODERMA AUTOANTIGEN 100 KDA) (PM/SCL-100) (P100 POLYMYOSITIS-SCLERODERMA OVERLAP SYNDROME ASSOCIATED AUTOANTIGEN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.474956\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.26784\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209431\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EXOSC10\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2664\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEOXYCYTIDYLATE DEAMINASE (EC 3.5.4.12) (DCMP DEAMINASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.124149\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.593022\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209349737\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DCTD\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2665\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ASPARTYL-TRNA SYNTHETASE (EC 6.1.1.12) (ASPARTATE--TRNA LIGASE) (ASPRS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.149127\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.712692\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209244667\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DARS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2666\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NEURAL CELL ADHESION MOLECULE L1 PRECURSOR (N-CAM L1) (CD171 ANTIGEN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.02527\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.120774\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209233775\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2667\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR MAFF (V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG F) (U-MAF). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0761231\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.363819\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209233438\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MAFF\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2668\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 3; NF-E2-RELATED FACTOR 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0877868\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.419564\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209233395\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFE2L3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2669\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION INITIATION FACTOR TFIID 31 KDA SUBUNIT (TAFII-31) (TAFII-32) (TAFII32). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.61918\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.95928\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209233327\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TAF9\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2670\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR MAFG (V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG G) (HMAF). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0798317\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.381544\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209233273\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2671\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"NUCLEAR FACTOR ERYTHROID 2 RELATED FACTOR 1 (NF-E2 RELATED FACTOR 1) (NFE2-RELATED FACTOR 1) (NUCLEAR FACTOR, ERYTHROID DERIVED 2, LIKE 1) (TRANSCRIPTION FACTOR 11) (TRANSCRIPTION FACTOR HBZ17) (TRANSCRIPTION FACTOR LCR-F1) (LOCUS CONTROL REGION-FACTOR 1)"\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0693641\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.331516\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209233039\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFE2L1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2672\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR MAFK (ERYTHROID TRANSCRIPTION FACTOR NF-E2 P18 SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0897053\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.428734\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209232998\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2673\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0251255\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.120084\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209232704\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NFASC\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2674\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CELL ADHESION MOLECULE WITH HOMOLOGY TO L1CAM PRECURSOR; NEURAL CELL ADHESION MOLECULE; CELL ADHESION MOLECULE L1-LIKE; L1 CELL ADHESION MOLECULE 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0249248\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.119125\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.209232319\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CHL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2675\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"TBP-ASSOCIATED FACTOR 9L; NEURONAL CELL DEATH-RELATED PROTEIN; TAF9-LIKE RNA POLYMERASE II, TATA BOX BINDING PROTEIN (TBP)-ASSOCIATED FACTOR, 31 KD; NEURONAL CELL DEATH-RELATED GENE IN NEURON-7; TRANSCRIPTION ASSOCIATED FACTOR TAFII31L; TRANSCRIPTION INIT"\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.383112\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.83532\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208743979\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TAF9B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2676\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
N-ACETYLGALACTOSAMINE KINASE (EC 2.7.1.-) (GALNAC KINASE) (GALACTOKINASE 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0435693\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.20874\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208725208\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GALK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2677\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE (EC 2.7.7.12) (GAL-1-P URIDYLYLTRANSFERASE) (UDP-GLUCOSE--HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0454701\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.217847\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208724931\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2678\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UDP-GLUCOSE 4-EPIMERASE (EC 5.1.3.2) (GALACTOWALDENASE) (UDP- GALACTOSE 4-EPIMERASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.234953\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.12566\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208724659\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GALE\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2679\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ACYL-COENZYME A OXIDASE 2, PEROXISOMAL (EC 1.3.3.6) (BRANCHED-CHAIN ACYL-COA OXIDASE) (BRCACOX) (TRIHYDROXYCOPROSTANOYL-COA OXIDASE) (THCCOX) (THCA-COA OXIDASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.663483\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.18084\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208587354\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ACOX2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2680\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POLY(A) POLYMERASE GAMMA (EC 2.7.7.19) (PAP GAMMA) (POLYNUCLEOTIDE ADENYLYLTRANSFERASE GAMMA) (SRP RNA 3' ADENYLATING ENZYME). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.377523\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.81111\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.20844841\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PAPOLG\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2681\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7 INTERACTING PROTEIN 1 (TAK1-BINDING PROTEIN 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.225506\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.08199\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208417823\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MAP3K7IP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2682\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXOCYST COMPLEX COMPONENT SEC5. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0545554\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.261799\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208386587\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EXOC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2683\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RETICULON PROTEIN 3 (NEUROENDOCRINE-SPECIFIC PROTEIN-LIKE 2) (NSP-LIKE PROTEIN II) (NSPLII). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.203468\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.976589\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208345578\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RTN3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2684\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POLY(A) POLYMERASE ALPHA (EC 2.7.7.19) (PAP) (POLYNUCLEOTIDE ADENYLYLTRANSFERASE ALPHA) (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.438432\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.10446\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.20833468\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PAPOLA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2685\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RETICULON PROTEIN 2 (NEUROENDOCRINE-SPECIFIC PROTEIN-LIKE 1) (NSP-LIKE PROTEIN 1) (NSPLI). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.175589\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.842838\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208330664\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RTN2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2686\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EH-DOMAIN CONTAINING PROTEIN 1 (TESTILIN) (HPAST1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.121\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.580932\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208285996\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EHD1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2687\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EH-DOMAIN CONTAINING PROTEIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.107786\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.517492\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208285345\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EHD3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2688\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EH-DOMAIN CONTAINING PROTEIN 4 (EH DOMAIN-CONTAINING PROTEIN FKSG7) (HEPATOCELLULAR CARCINOMA-ASSOCIATED PROTEIN 10/11). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0943663\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.453066\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208283782\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EHD4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2689\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EH-DOMAIN CONTAINING PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0892656\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.428577\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208283692\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EHD2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2690\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SIN3 ASSOCIATED POLYPEPTIDE P18 (2HOR0202). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0937258\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.450013\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208273539\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SAP18\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2691\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RETICULON 1 (NEUROENDOCRINE-SPECIFIC PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.268811\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.29069\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.20826922\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RTN1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2692\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RETICULON 4 (NEURITE OUTGROWTH INHIBITOR) (NOGO PROTEIN) (FOOCEN) (NEUROENDOCRINE-SPECIFIC PROTEIN) (NSP) (NEUROENDOCRINE SPECIFIC PROTEIN C HOMOLOG) (RTN-X) (RETICULON 5) (MY043 PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.267978\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.28698\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.20822235\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RTN4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2693\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.122185\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.586832\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208211209\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
AIFM3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2694\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"STEROID HORMONE RECEPTOR ERR1 (ESTROGEN-RELATED RECEPTOR, ALPHA) (ERR-ALPHA) (ESTROGEN RECEPTOR-LIKE 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.13519\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.649418\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.208171009\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ESRRA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2695\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
T-BOX TRANSCRIPTION FACTOR TBX6 (T-BOX PROTEIN 6). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.018755\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0901743\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207986089\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TBX6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2696\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ENDONUCLEASE G, MITOCHONDRIAL PRECURSOR (EC 3.1.30.-) (ENDO G). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0410294\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.19727\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207986009\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ENDOG\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2697\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PROGRAMMED CELL DEATH PROTEIN 8, MITOCHONDRIAL PRECURSOR (EC 1.-.-.-) (APOPTOSIS-INDUCING FACTOR). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.112229\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.5396\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207985545\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
AIFM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2698\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ESTROGEN-RELATED RECEPTOR GAMMA (ESTROGEN RECEPTOR RELATED PROTEIN 3) (ERR GAMMA-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.151787\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.730409\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207810966\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2699\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L (HNRNP L). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.100335\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.482909\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207772065\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HNRNPL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2700\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0804074\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.387009\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207766228\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HNRPLL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2701\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
METAXIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.133976\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.645054\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.20769734\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MTX1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2702\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.145039\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.698388\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207676821\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FAM82B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2703\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MONOGLYCERIDE LIPASE; LYSOPHOSPHOLIPASE-LIKE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0986882\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.475276\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207643979\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MGLL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2704\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR, 73 KDA SUBUNIT (CPSF 73 KDA SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.412088\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.98586\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207511104\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CPSF3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2705\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.119287\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.574873\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207501483\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABHD14B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2706\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"STEROID HORMONE RECEPTOR ERR2 (ESTROGEN-RELATED RECEPTOR, BETA) (ERR-BETA) (ESTROGEN RECEPTOR-LIKE 2) (ERR BETA-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.175846\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.847805\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207413261\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ESRRB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2707\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.542979\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.61855\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.207358653\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/